Efficacy of thalidomide plus MP regimen for treatment of the patients with multiple myeloma

VernacularTitle:沙利度胺联合MP方案治疗多发性骨髓瘤的疗效评价
Author: Yajie WANG ; Xiumin SHI ; Sujun GAO
Publication Type:Journal Article
Keywords: Multiple myeloma; Antineoplastic combined chemotherapy protocds; Thalidomide
From: Journal of Leukemia & Lymphoma 2011;20(2):82-85
CountryChina
Language:Chinese
Abstract: Objective To compare the efficacy and toxicity of melphalan + prednisone + thalidomide regimen (MPT) and melphalan + prednisone regimen (MP) in the treatment of multiple myeloma (MM).was given 100-200 mg/d everyday. 21 cases in MP group, the dose of melphalan and prednisone were the same as that in MPT group. The efficacy was evaluated after 6 cycles of treatment. Results The overall response rate (ORR) of MPT group and MP group were 65.4 % and 42.9 %, respectively (P＞O.05). The median response time in MPT group versus MP group was 2 months versus 3 months. Compared with the MP group. the increase of hemoglobin and albumin concentration in the MPT group is significantly higher (P＜ 0.05).The incidence of adverse effects of MPT group was higher than that of MP group (P ＜0.05), but the percentage of grade 3 and grade 4 toxicity was no different. The median PFS in MPT group was 11 months, 2-year PFS was 66.18 %. Conclusion Compared with MP, MPT could achieve higher response rate, improve the life quality and prolong the survival time of MM patients with better tolerance.